89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)
The main purposes of this study include:

Looking at the way the body absorbs, distributes, and gets rid of 89Zr-DFO-REGN3767

Finding the best dose amount of 89Zr-DFO-REGN3767

Finding the best time for PET scanning after injection of 89Zr-DFO-REGN3767
Large B-cell Lymphoma|DLBCL
DRUG: 89Zr-DFO-REGN3767|DIAGNOSTIC_TEST: PET/CT
Biodistribution of 89Zr-DFO-REGN3767, A PET/CT scan extending from top of skull to feet will be performed to determine the biodistribution of 89Zr-DFO-REGN3767, 2 years|Optimal 89Zr-DFO-REGN3767 mass dose for tumor targeting, Determine the optimal 89Zr-DFO-REGN3767 mass dose for tumor targeting, 2 years|Optimal time for imaging and tumor uptake post 89Zr-DFO-REGN3767 administration, Determine the optimal time for imaging and tumor uptake post 89Zr-DFO-REGN3767 administration, 2 years|Tumor lesion uptake of 89Zr-DFO-REGN3767 and correlate with LAG-3 expression by IHC, Evaluate tumor lesion uptake of 89Zr-DFO-REGN3767 and correlate with LAG-3 expression by IHC in tumors will be compared descriptively with other biomarkers of tumor immune environment characterized in biopsies, such as quantitation of IHC score (LAG-3 and / or other immune cell markers), or other biomarker measures., 2 years
The main purposes of this study include:

Looking at the way the body absorbs, distributes, and gets rid of 89Zr-DFO-REGN3767

Finding the best dose amount of 89Zr-DFO-REGN3767

Finding the best time for PET scanning after injection of 89Zr-DFO-REGN3767